Can TrilliumBiO and Oncobit make MRD monitoring standard for uveal melanoma in the U.S.?
TrilliumBiO and Oncobit launch a ctDNA-based monitoring platform for uveal melanoma in the U.S. Learn how this could change rare cancer care in 2026.
Medical Devices & Diagnostics